Hologic Ranked #1 for Mammography System Performance and Customer Satisfaction for 10th Consecutive Year
December 01 2022 - 8:05AM
Business Wire
Global Leader in Women’s Health Recognized with
Three IMV ServiceTrak™ Awards for Mammography During RSNA 2022
Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology
company primarily focused on improving women’s health, swept the
2022 IMV ServiceTrak™ Awards for Mammography, taking home awards
for Best Service, Best Customer Satisfaction and Best System
Performance. This is the 10th consecutive year that Hologic has
ranked first in the industry for Mammography System Performance and
Customer Satisfaction and the eighth year for Mammography
Service.
“We are thrilled to win the IMV Award for a 10th year and need
to acknowledge our outstanding service team that has kept us on top
of the IMV leaderboard,” said Erik Anderson, President of the
Breast and Skeletal Health Solutions Division at Hologic. “Because
of their focus and dedication, we’ve delivered exceptional outcomes
and experiences for our customers and the patients they serve. We
look forward to the next 10 years.”
Hologic is the company behind the Genius® 3D
Mammography™ exam, the only mammogram approved by the FDA as
superior to conventional mammography for all women, including those
with dense breasts.1 It also detects 20%-65% more invasive breast
cancers compared to 2D mammography alone.2
SureCare® Service from Hologic offers a variety of
service plans designed to help customers get the most out of their
systems. SureCare plan options include maximum uptime guarantees,
predictive analytics* to address equipment issues before they occur
and state-of-the-art connectivity to provide real-time insights on
optimizing business and clinical outcomes.
Hologic’s strong team of veteran service and support experts
includes factory-trained field engineers solely focused on
servicing Hologic systems and highly qualified clinical
applications specialists who assist new users along every step of
setup, on-site training and beyond.
“We are honored to receive this recognition from IMV once again
as it underscores the team’s partnership with our customers,” said
Mark Horvath, Corporate Vice President, Global Services. “We are
deeply committed to supporting our customers through our SureCare
Service offerings so they can focus on what’s most important –
providing exceptional care to their patients.”
To learn more about SureCare Service from Hologic, visit
www.Hologic.com/SureCare-Service.
About Hologic, Inc.
Hologic, Inc. is a global medical technology innovator primarily
focused on improving women’s health and well-being through early
detection and treatment. Its advancements include invention of the
world’s first commercial 3D mammography system to fight breast
cancer; leadership in testing for cervical cancer, sexually
transmitted infections, respiratory illnesses, and the virus that
causes COVID-19; and minimally invasive surgical technologies for
uterine fibroids and abnormal uterine bleeding.
The company also champions women through the Hologic Global
Women’s Health Index, which provides a science-backed data roadmap
for improving women’s well-being, and Project Health Equality,
which elevates awareness, research insights and access to quality
care for underserved women.
Forward-Looking
Statements
This news release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic products. There can be no assurance these products
will achieve the benefits described herein or that such benefits
will be replicated in any particular manner with respect to an
individual patient, as the actual effect of the use of the products
can only be determined on a case-by-case basis. In addition, there
can be no assurance that these products will be commercially
successful or achieve any expected level of sales. Hologic
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements presented
herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such data or
statements are based.
This information is not intended as a product solicitation or
promotion where such activities are prohibited. For specific
information on what products are available for sale in a particular
country, please contact a local Hologic sales representative or
write to womenshealth@hologic.com.
SOURCE: Hologic, Inc.
_________________________ * Available on select systems 1 FDA
Approvals P080003, P080003/S001, P080003/S004, P080003/S005 2
Results from Friedewald, SM, et al. "Breast cancer screening using
tomosynthesis in combination with digital mammography." JAMA 311.24
(2014): 2499-2507; a multi-site (13), non-randomized, historical
control study of 454,000 screening mammograms investigating the
initial impact the introduction of the Hologic Selenia® Dimensions
® on screening outcomes. Individual results may vary. The study
found an average 41% (95% CI: 20-65%) increase and that 1.2 (95%
CI: 0.8-1.6) additional invasive breast cancers per 1000 screening
exams were found in women receiving combined 2D FFDM and 3D™
mammograms acquired with the Hologic 3D Mammography™ System versus
women receiving 2D FFDM mammograms only.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221201005352/en/
Media Contact: Jane Mazur Vice President, Global
Communications (+1) 508.263.8764 jane.mazur@hologic.com
Investor Contact: Ryan Simon Vice President, Investor
Relations (+1) 858.410.8514 ryan.simon@hologic.com
Hologic (NASDAQ:HOLX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hologic (NASDAQ:HOLX)
Historical Stock Chart
From Jul 2023 to Jul 2024